Nexvax2 is a potential vaccine for celiac disease created by ImmusanT.
Nexvax2 is a therapeutic vaccine that combines three proprietary peptides that elicit an immune response in patients with celiac disease who carry the immune recognition gene HLA-DQ2. In an approach similar to treatments for allergies to dander from cats and dust mites, Nexvax2 is designed to reprogram gluten-specific T cells triggered by the patient’s immune response to the protein. The goal is for Nexvax2 to restore celiac patients’ immune tolerance to gluten, reduce inflammation in the nutrient-absorbing villi that line the small intestine, return the intestine to a healthy state, and allow patients to eat a normal diet.
Nexvax2 is currently in Phase 1-b human trials, and the company claims to be aiming for a 2017 (or in 5–10 years)mass market product launch.